Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature

Maroufi, Seyed Farzad; Behdani, Fereshteh Naderi; Rezania, Fatemeh; Khotbehsara, Samaneh Tanhapour; Mirzaasgari, Zahra

doi:10.1080/21645515.2022.2040239

Cited by 27 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maroufi et al reported a case of transverse myelitis after vaccination with the AstraZeneca COVID-19 vaccine, a modified chimpanzee adenovirus vector vaccine. 1 This severe adverse effect has also been reported with mRNA COVID-19 vaccines from Pfizer/BioNTech and Moderna, including the case that we reported. 2–14 As of 18 March 2022, the Vaccine Adverse Event Reporting System (VAERS) CDC Wonder database reports 154 events of myelitis or transverse myelitis with the Pfizer/BioNTech vaccine, 111 events with the Moderna vaccine and 40 events with the Janssen/J&J vaccine in the U.S. Not only are most of the patients who experience this vaccine-related severe adverse event contraindicated from receiving additional COVID-19 vaccines, they often receive prolonged courses of corticosteroids for the control of the spinal cord inflammation which may further increase infectious risk.…”

supporting

confidence: 77%

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

Fitzsimmons

2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Individuals who experience severe COVID-19-vaccine-related adverse reactions such as transverse myelitis may be precluded from receiving further vaccination to protect from SARS-CoV-2 infection. Although the mechanism of autoimmune spinal cord inflammation resulting in transverse myelitis is unclear, it may be safe to administer antibody therapy for preventing COVID-19. Recently, Evusheld, tixagevimab with cilgavimab, two spike-protein directed monoclonal antibodies were authorized by the U.S. FDA and U.K. MHRA for administration to individuals when vaccination is not recommended. We report the safe administration of Evusheld to a patient who experienced transverse myelitis 11 months previously as a result of receiving the Moderna mRNA vaccine. This patient has experienced no adverse events to Evusheld. Additional experience and data collection are warranted to determine the safety of this prophylactic therapy.

show abstract

supporting

confidence: 77%

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

Fitzsimmons

2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The PRISMA flowchart ( Figure 1 ) showed a search strategy for our review. The present study consisted of 28 studies, including 26 case reports, one case series, and one cross-sectional, and the pooled data of 31 patients with COVID-19 vaccine-associated ATM is extracted ( Sriwastava et al, 2021 , Sepahvand et al, 2022 , Tan et al, 2021 , Corrêa et al, 2021 , Vegezzi et al, 2021 , Hsiao et al, 2021 , Pagenkopf and Südmeyer, 2021 , Notghi et al, 2021 , Gao et al, 2021 , Malhotra et al, 2021 , Khan et al, 2022 , Erdem et al, 2021 , Hirose et al, 2021 , Tahir et al, 2021 , Miyaue et al, 2021 , Fujikawa et al, 2021 , Kaulen et al, 2022 , McLean and Trefts, 2021 , Alabkal et al, 2021 , Fitzsimmons and Nance, 2021 , Nakano et al, 2022 , Spataro et al, 2022 , Cabral et al, 2022 , Khan et al, 2022 , Maroufi et al, 2022 , Eom et al, 2022 , Netravathi et al, 2022 , Esechie et al, 2022 ). All of the selected studies were written in the English language.…”

Section: Resultsmentioning

confidence: 99%

Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review

Ostovan¹,

Sahraian²,

Karazhian³

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…Very rarely central nervous system autoimmune diseases were also described in association with the COVID-19 vaccine [71]. Different potential mechanisms can be suggested for the possible association of autoimmune diseases after vaccination.…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barré Syndrome in Association with COVID-19 Vaccination: A Systematic Review

Abolmaali

Rezania

Behnagh

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Since the beginning of worldwide vaccination against coronavirus disease 2019 (COVID-19), studies have reported a possible association between vaccination and Guillain-Barré syndrome (GBS). In this regard, we conducted a systematic review assessing different demographic, clinical, and neurophysiological aspects of patients with GBS following immunization with COVID-19 vaccines. A comprehensive search of PubMed, Web of Science, Scopus, and Google Scholar was performed. Articles in English between January 2020 and November 2021 were included. Data on demographics, clinical characteristics, vaccines information, treatment approaches, and outcomes were extracted. The data of a total of 88 patients out of 41 studies was included. The mean age of patients was 58.7 ± 16.6 years and 55 cases (62.5%) were male. AstraZeneca was the most-reported vaccine associated with GBS with 52 cases (59.1%) followed by Pfizer with 20 cases (22.7%). GBS occurred after the first dose of vaccination in 70 cases (79.5%). The mean time interval between vaccination and symptom onset was 13.9 ± 7.4 days. Limb weakness (47.7%), sensory disturbance (38.6%), and facial weakness (27.3%) were the most common reported symptoms, respectively. Albuminocytologic dissociation was seen in 65% of patients who underwent lumbar puncture (n = 65). Acute inflammatory demyelinating polyradiculopathy was the most common GBS subtype, which was reported in 38 patients (43.2%). While one-fifth of patients underwent intubation (n = 17), a favorable outcome was achieved in the majority of subjects (n = 46, 63%). Overall, a small rise in GBS incidence, following various COVID-19 vaccines, was observed. Notably, 85% of affected individuals experienced at least a partial recovery.

show abstract

Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature

Cited by 27 publications

References 23 publications

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review

Guillain-Barré Syndrome in Association with COVID-19 Vaccination: A Systematic Review

Contact Info

Product

Resources

About